Artificial liver: review and Cedars-Sinai experience.
During the past decade, whole organ transplantation has become the only clinically effective method of treating fulminant hepatic failure and chronic liver failure due to specific genetic, hepatocellular, and anatomic defects of liver function. However, wider application of liver transplantation is restricted by shortage of organ donors, high cost, relatively high morbidity, and need for life-long immunosuppression. As a result, investigators have attempted to develop alternative methods to treat liver insufficiency. These ranged from use of plasma exchange to utilization of detoxification columns and extracorporeal devices loaded with various liver tissue preparations. Recently, advances in hepatocyte isolation and culture techniques, improved understanding of hepatocyte-matrix interactions, availability of new biomaterials, improved hollow-fiber technology, and better understanding of flow and mass transport across semipermeable membranes have resulted in the development of a new generation of liver assist devices. Some of these devices, including the one developed by the authors, are currently being tested in the clinical setting. In this paper, the past experience with liver support systems is reviewed, the present status of the field is critically examined, and the results of a phase I clinical trial with the bioartificial liver, utilizing primary porcine hepatocytes, are summarized.
Kamohara
Y
Y
Department of Surgery and Liver Support Unit, Cedars-Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Blvd., R-8015, Los Angeles, CA 90048, USA.
Rozga
J
J
Demetriou
A A
AA
D000328:Adult; D000818:Animals; D016022:Case-Control Studies; D017690:Cell Transplantation; D005260:Female; D006801:Humans; D008099:Liver / Q000166:cytology; D017093:Liver Failure / Q000628:therapy*; D016031:Liver Transplantation; D019164:Liver, Artificial; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome